# US 2020/0223826 A1 · Glucose-6-Phosphate Dehydrogenase (G6PD)-Modulating Agents And Methods Of Treating G6PD Deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0223826 A1
- Document ID: US20200223826A1
- Status: Published application
- Kind: A1
- Application number: 16/632,863
- Filed: 2018-07-24
- Published: 2020-07-16
- Earliest claimed: 2017-07-25
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Sunhee Hwang; DARIA MOCHLY-ROSEN; CHE-HONG CHEN; Andrew Goodwin Raub
- Web page: https://patentgrep.com/patent/US20200223826A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07C 211/16: of a saturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C 211/27: having amino groups linked to the six-membered aromatic ring by saturated carbon chains
- C07C 211/42: with six-membered aromatic rings being part of the condensed ring systems
- C07C 215/32: containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
- C07C 223/02: having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C 225/16: and containing six-membered aromatic rings
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 213/36: Radicals substituted by singly-bound nitrogen atoms (nitro radicals C07D213/26)
- C07D 317/58: Radicals substituted by nitrogen atoms (nitro radicals C07D317/52)
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 407/10: linked by a carbon chain containing aromatic rings
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 471/06: Peri-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/10: Spiro-condensed systems
- C07B 2200/07: Optical isomers
- C07C 2602/24: the ring system containing nine carbon atoms, e.g. perhydroindane
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Aspects of the present disclosure include G6PD-modulating agents and methods for modulating a glucose-6-phosphate dehydrogenase (G6PD) in a sample using such agents. A G6PD-modulating agent can be dimeric and include two terminal carbocyclic or heterocyclic groups connected via a linker. In some instances, the agent includes a diamino-containing linker. In certain cases, the agent includes two amino substituents. Also provided are methods for treating a subject for a G6PD deficiency-associated condition, that include administering to a subject an effective amount of a G6PD-modulating agent to selectively activate a mutant G6PD and treat the subject. Kits and compositions for practicing the subject methods are also provided.

## Claims

### Claim 1

A G6PD-modulating agent of the formula (I):
Z1—Y—Z2 (I)
wherein:
Z1 and Z2 are independently selected from an aryl, a substituted aryl, a heteroaryl, a substituted heteroaryl, a carbocycle, a substituted carbocycle, a heterocycle and a substituted heterocycle, wherein optionally Z1 and Z2 are each independently substituted with an amino-containing substituent comprising an amino group; and
Y is a central linking unit, optionally comprising two amino groups separated via a linker;
wherein the agent comprises at least two amino groups configured at a distance of about 4-15 angstroms,
or a salt thereof.

### Claim 2 (depends on 1)

The G6PD-modulating agent of claim 1, wherein the agent is of formula (Ia):
Z1-T1-Y-T2-Z2 (Ia)
wherein:
T1 and T2 are each independently a covalent bond or a linker; and
Y is the central linking unit and comprises two amino groups.

### Claim 3 (depends on 1)

The G6PD-modulating agent of claim 1, wherein the agent is of formula (IIa):
Z1-T1-N(R1)xp+-L1-N(R2)yq+-T2-Z2;
wherein:
R1 and R2 are independently H, an alkyl, a substituted alkyl; and
L1 is a central linker; and
x and y are independently 1 or 2, wherein:
when x is 1, p is 0;
when x is 2, p is 1;
when y is 1, q is 0; and
when y is 2, q is 1.

### Claim 4 (depends on 3)

The G6PD-modulating agent of claim 3, wherein the agent is of the formula:
Z1-T1-N(R1)-L1-N(R2)-T2-Z2.

### Claim 5 (depends on 1)

The G6PD-modulating agent of claim 1, wherein the agent is of formula (Ib):
N(R1)xp+-T1-Z1-L2-Z2-T2-N(R2)yq+ (Ib)
wherein:
T1 and T2 are each independently a covalent bond or a linker;
R1 and R2 are independently H, an alkyl, a substituted alkyl; and
L2 is a central linker; and
x and y are independently 2 or 3, wherein:
when x is 2, p is 0;
when x is 3, p is 1;
when y is 2, q is 0; and
when y is 3, q is 1.

### Claim 6 (depends on 5)

The G6PD-modulating agent of claim 5, wherein the agent is of the formula:
N(R1)2-T1-Z1-L2-Z2-T2-N(R2)2.

### Claim 7 (depends on 1)

The G6PD-modulating agent of claim 1, wherein the agent is of formula (IIb):
Z1-T1-(NHetN)-T2-Z2 (IIb)
wherein:
—(NHetN)— is a bivalent heterocyclic linking ring system having 1 to 4 rings and comprising a first tertiary amino group connected to T1 and a second tertiary amino group connected to T2.

### Claim 8 (depends on 7)

The G6PD-modulating agent of claim 7, wherein —(NHetN)— is selected from one of the following structures:

### Claim 9 (depends on 6)

The G6PD-modulating agent of claim 6, wherein L1 is of the formula:
-L11-Z3-L12-
wherein:
L11 and L12 are independently alkyl, substituted alkyl or a polyethylene glycol (PEG) moiety; and
Z3 is selected from a covalent bond, a cycloalkyl, an aryl, a heteroaryl, a bicyclic carbocycle, a cubane, an alkenyl, an allenyl, an alkynyl and a cleavable group.

### Claim 10 (depends on 3)

The G6PD-modulating agent of claim 3, wherein L1 is —(CH2)n— wherein n is 2-12.

### Claim 11 (depends on 5)

The G6PD-modulating agent of claim 5, wherein L2 is selected from 4,4′-biphenyl, ethynylene-1,4-phenylene-ethynylene and 1,4-phenylene-ethynylene-1,4-phenylene.

### Claim 12 (depends on 1)

The G6PD-modulating agent of claim 1, wherein Z1 and Z2 are independently selected from indole, substituted indole, benzofuran, substituted benzofuran, benzothiophene, substituted benzothiophene, phenyl, substituted phenyl, quinoline, substituted quinoline, 1,3-benzodioxole, substituted 1,3-benzodioxole, thiophene, substituted thiophene, 2,3-dihydro-1H-indene, substituted 2,3-dihydro-1H-indene, pyridyl and substituted pyridyl.

### Claim 13 (depends on 1)

The G6PD-modulating agent of claim 1, wherein Z1 and Z2 are independently selected from one of the following:
4-pyridyl, substituted 4-pyridyl, 3-pyridyl, substituted 3-pyridyl, 3-pyridyl, substituted 3-pyridyl, 2-thiophenyl, substituted 2-thiophenyl,
wherein:
Z11 is O, S or NR, wherein R is H, alkyl or substituted alkyl;
s is 0-4;
each R21 is independently alkyl, substituted alkyl, halogen, hydroxy, alkoxy, substituted alkoxy, cyano, nitro, formyl (—CHO), sulfonic acid, carboxylic acid, sulfonamide or carobxyamide; and
R11 is hydrogen, alkyl or substituted alkyl.

### Claim 14 (depends on 5)

The G6PD-modulating agent of claim 5, wherein Z1 and Z2 are independently selected from the following:
wherein:
Z11 is O, S or NR, wherein R is H, alkyl or substituted alkyl;
s is 0-4 (e.g., 0, 1 or 2);
each R21 is independently alkyl, substituted alkyl, halogen (e.g., chloro, bromo or fluoro), hydroxy, alkoxy, substituted alkoxy, cyano, nitro, formyl (—CHO), sulfonic acid, carboxylic acid, sulfonamide or carobxyamide; and
R11 is hydrogen, alkyl or substituted alkyl. In some cases of Z1 and Z2, x is 2 and p is 0.

### Claim 15 (depends on 1)

An erythrocyte preservative composition, comprising a G6PD-modulating agent of claim 1.

### Claim 16 (depends on 1)

A pharmaceutical composition, comprising a G6PD-modulating agent of claim 1 and a pharmaceutically acceptable excipient.

### Claim 17 (depends on 1)

A method for modulating a glucose-6-phosphate dehydrogenase (G6PD) in a sample, the method comprising:
contacting a sample comprising a G6PD with a G6PD-modulating agent of claim 1 to modulate the activity of the G6PD in the sample.

### Claim 18 (depends on 17)

The method of claim 17, wherein the agent increases the storage stability of a sample of erythrocyte cells.

### Claim 19 (depends on 1)

A method for treating a subject for a G6PD deficiency-associated condition, the method comprising:
administering to a subject in need thereof an effective amount of a G6PD-modulating agent according to claim 1 to activate a mutant G6PD and treat the subject for the G6PD deficiency-associated condition.

### Claim 20 (depends on 19)

The method of claim 19, wherein the subject is undergoing treatment with a drug that precipitates hemolysis in G6PD-deficient individuals.
